Spero therapeutics announces first patient, first visit for phase 3 pivot-po trial evaluating tebipenem hbr in complicated urinary tract infections

$95 million in development milestones payable over two years, as part of gsk license agreement $95 million in development milestones payable over two years, as part of gsk license agreement

SPRO Ratings Summary

SPRO Quant Ranking